Development of Therapeutic Proteins for a New Subcutaneous Route of Administration After the Establishment of Intravenous Dosages: A Systematic Review-Reference-Cited by-同舟云学术

Development of Therapeutic Proteins for a New Subcutaneous Route of Administration After the Establishment of Intravenous Dosages: A Systematic Review

Published:2023-01-09 Issue:5 Volume:113 Page:1011-1029
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin Pharma and Therapeutics

Author:

Xu Zhenhua¹,Leu Jocelyn H.¹,Xu Yan¹²,Nnane Ivo¹,Liva Sophia G.¹,Wang‐Lin Shun Xin¹³,Kudgus‐Lokken Rachel⁴,Vermeulen An⁵,Ouellet Daniele¹

Affiliation:

1. Clinical Pharmacology and Pharmacometrics Janssen Research and Development, LLC. Spring House Pennsylvania USA

2. Current address: Clinical Pharmacology Simcere Pharmaceuticals Cambridge Massachusetts USA

3. Current address: Nanjing Linkinovo Biological Technology Research Institute Nanjing Jiangsu China

4. Clinical Pharmacology Allucent Cary North Carolina USA

5. Clinical Pharmacology and Pharmacometrics, Janssen Research & Development, a division of Janssen Pharmaceutica NV Beerse Belgium

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2823

Reference51 articles.

1. Patient Preferences for Subcutaneous versus Intravenous Administration of Treatment for Chronic Immune System Disorders: A Systematic Review

2. Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab)

3. Non-Clinical Pharmacokinetic/Pharmacodynamic and Early Clinical Studies Supporting Development of a Novel Subcutaneous Formulation for the Monoclonal Antibody Rituximab

4. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial

5. Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open‐label Phase II study

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent approaches of antibody therapeutics in androgenetic alopecia;Frontiers in Pharmacology;2024-08-16

2. Assessing Physicochemical Stability of Monoclonal Antibodies in a Simulated Subcutaneous Environment;Journal of Pharmaceutical Sciences;2024-07

3. Clinical Pharmacology Strategies for Bispecific Antibody Development: Learnings from FDA‐Approved Bispecific Antibodies in Oncology;Clinical Pharmacology & Therapeutics;2024-06-02

4. INVESTIGATING THE PHYSICOCHEMICAL, NON-CLINICAL, AND CLINICAL CRITERIA FOR ASSESSING COMPARABILITY IN RANIBIZUMAB BIOSIMILARS: A COMPREHENSIVE REVIEW;FARMACIA;2024

5. Long-Acting Strategies for Antibody Drugs: Structural Modification, Controlling Release, and Changing the Administration Route;European Journal of Drug Metabolism and Pharmacokinetics;2024-04-18